REGN vs TAK: stock comparison and AI forecast
Regeneron Pharmaceuticals, Inc. (REGN) and Takeda Pharmaceutical Co Ltd (TAK) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
REGN Regeneron Pharmaceuticals, Inc.
- Price
- $961.26 +35.5% · 6M
- Market Cap
- $100.21B
- P/E Ratio
- 21.6x
- Size
- large-cap
- AI Forecast
TAK Takeda Pharmaceutical Co Ltd
- Price
- $20.01 +20.0% · 6M
- Market Cap
- $62.51B
- P/E Ratio
- 6.0x
- Size
- large-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- REGN is 1.6 times larger than TAK by market capitalization ($100.21B against $62.51B).
- TAK trades at 6.0 times trailing earnings, REGN at 21.6 times.
- Over the last six months REGN returned +35.5% and TAK +20.0%.
- REGN turns 36.5% of its revenue into net income, against 4.9% for TAK.
- REGN yields 0.38% in dividends; TAK pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | REGN | TAK |
|---|---|---|
| Market Cap | $100.21B | $62.51B |
| P/E Ratio | 21.55x | 6.02x |
| P/B Ratio | 2.99x | – |
| Dividend Yield | 0.38% | – |
| EPS | $45.18 | $3.32 |
| Book Value/Share | $325.37 | – |
| Revenue/Share | $164.11 | $34.55 |
| FCF/Share | $37.16 | $6.79 |
Profitability & Margins
| Metric | REGN | TAK |
|---|---|---|
| ROE | 18.4% | – |
| ROA | 13.9% | – |
| ROIC | 12.7% | – |
| Gross Margin | – | 67.4% |
| Operating Margin | 28.8% | 9.2% |
| Net Margin | 36.5% | 4.9% |
| EBT Margin | 33.6% | 5.5% |
| Tax Rate | 15.3% | 11.7% |
Financial Health
| Metric | REGN | TAK |
|---|---|---|
| Current Ratio | 3.35x | – |
| Quick Ratio | 2.89x | – |
| D/E Ratio | 0.33x | – |
| Financial Leverage | 1.33x | – |
| Interest Coverage | 21.1x | – |
| Working Capital | $14.59B | – |
Cash Flow
| Metric | REGN | TAK |
|---|---|---|
| Operating Cash Flow | $4.85B | $25.43B |
| Free Cash Flow | $3.83B | $21.23B |
| Capital Spending | -$1.02B | -$4.20B |
| OCF Growth YoY | -4.4% | – |
| FCF Growth YoY | -9.4% | 0.0% |
| FCF/Sales | 22.6% | 19.7% |
| CapEx/Sales | 6.0% | 3.9% |
Operational Efficiency
| Metric | REGN | TAK |
|---|---|---|
| Asset Turnover | 0.38x | – |
| Receivables Turnover | 2.2x | – |
| Fixed Assets Turnover | 3.0x | – |
| Days Sales Outstanding | 164 days | – |
Income Statement
| Metric | REGN | TAK |
|---|---|---|
| Total Revenue | $16.90B | $107.93B |
| Operating Income | $4.86B | $9.90B |
| Net Income | $6.17B | $5.25B |
| R&D Expense | $6.60B | $17.20B |
| SG&A Expense | $2.76B | – |
| Cost of Goods Sold | – | $35.17B |
Dividend & Shareholder Information
| Metric | REGN | TAK |
|---|---|---|
| Dividends Per Share | $3.72 | – |
| Payout Ratio | 8.2% | – |
| Shares Outstanding | 103M | 3124M |
| Net Income Growth | 220.3% | – |
| EPS Growth | 8.0% | – |
REGN vs TAK: stock comparison and AI forecast
Which is bigger, REGN or TAK?
REGN is 1.6 times larger than TAK by market capitalization ($100.21B against $62.51B).
Which is cheaper on earnings, REGN or TAK?
TAK trades at 6.0 times trailing earnings, REGN at 21.6 times.
Which stock performed better over the last six months, REGN or TAK?
Over the last six months REGN returned +35.5% and TAK +20.0%.
Which one does Intratio's AI model rank higher, REGN or TAK?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.